摘要
调节性T细胞(Treg)介导的克隆抑制,是引起肿瘤免疫耐受的主要因素之一。而吲哚胺2,3双加氧酶(IDO)通过对Treg细胞的作用下调各系统肿瘤微环境中的免疫反应,从而诱导宿主免疫耐受的形成。IDO抑制剂1-MT将有望成为治疗肿瘤的新靶点。
Clonal suppression induced by CD4 ^+ CD25 ^+ regulatory T cells is one of the principal factors to evoke the immune tolerance in tumor. Through the activation of CD^4+ CD25 ^+ regulatory T cells, the indoleamine 2,3-dioxygenase (IDO) reduces the immune response in tumor micro-environment of various systems, and induces the formation of host immune tolerance. IDO inhibitor 1 - MT is expected to become a new target for cancer treatment.
出处
《国际肿瘤学杂志》
CAS
2010年第4期276-278,共3页
Journal of International Oncology